Neuroimaging in the early diagnosis of neurodegenerative disease

Functional imaging may be useful for both the early diagnosis as well as preclinical detection of neurodegenerative disease. Additionally, while structural imaging has traditionally been regarded as a tool to exclude alternate diagnoses, recent advances in magnetic resonance show promise for greater diagnostic specificity. The role of MR and radionuclide imaging in early diagnosis and preclinical detection of dementia and parkinsonism are reviewed here.

[1]  Dag Aarsland,et al.  Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. , 2004, Archives of neurology.

[2]  T. Ishikawa,et al.  The Metabolic Topography of Parkinsonism , 1994, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  J O Rinne,et al.  Amyloid PET imaging in patients with mild cognitive impairment , 2011, Neurology.

[4]  C D Marsden,et al.  Differing patterns of striatal 18F‐dopa uptake in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy , 1990, Annals of neurology.

[5]  C. DeCarli,et al.  FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer's disease. , 2007, Brain : a journal of neurology.

[6]  John T. O'Brien,et al.  Diffusion tensor imaging in dementia with Lewy bodies and Alzheimer's disease , 2007, Psychiatry Research: Neuroimaging.

[7]  A. Kertesz,et al.  Volumetric study of lobar atrophy in Pick complex and Alzheimer’s disease , 2000, Journal of the Neurological Sciences.

[8]  M. Yoshita,et al.  Differentiation of idiopathic Parkinson's disease from striatonigral degeneration and progressive supranuclear palsy using iodine-123 meta-iodobenzylguanidine myocardial scintigraphy , 1998, Journal of the Neurological Sciences.

[9]  Michael J. Adam,et al.  Positron emission tomography after MPTP: observations relating to the cause of Parkinson's disease , 1985, Nature.

[10]  D. Loewenstein,et al.  A Comparative Analysis of Structural Brain MRI in the Diagnosis of Alzheimer’s Disease , 2009, Behavioural neurology.

[11]  N. Quinn,et al.  Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: An 18F‐dopa PET progression study , 2009, Movement disorders : official journal of the Movement Disorder Society.

[12]  R P Maguire,et al.  Complementary PET studies of striatal neuronal function in the differential diagnosis between multiple system atrophy and Parkinson's disease. , 1997, Brain : a journal of neurology.

[13]  M. Bobinski,et al.  Prediction of cognitive decline in normal elderly subjects with 2-[18F]fluoro-2-deoxy-d-glucose/positron-emission tomography (FDG/PET) , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[14]  R. Killiany,et al.  Use of structural magnetic resonance imaging to predict who will get Alzheimer's disease , 2000, Annals of neurology.

[15]  Aldo Quattrone,et al.  Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[16]  J. Molinuevo,et al.  Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study , 2011, The Lancet Neurology.

[17]  G. Frisoni,et al.  Functional network disruption in the degenerative dementias , 2011, The Lancet Neurology.

[18]  G. Arabia,et al.  MRI measurements predict PSP in unclassifiable parkinsonisms , 2011, Neurology.

[19]  Anna Barnes,et al.  FDG PET in the differential diagnosis of parkinsonian disorders , 2005, NeuroImage.

[20]  M. De Hert,et al.  Cost of disorders of the brain in Europe. , 2006, European journal of neurology.

[21]  Chris C. Tang,et al.  Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis , 2010, The Lancet Neurology.

[22]  H. Engler,et al.  PET imaging of amyloid deposition in patients with mild cognitive impairment , 2008, Neurobiology of Aging.

[23]  J. Olesen,et al.  Cost of disorders of the brain in Europe , 2005, European journal of neurology.

[24]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[25]  A. Stefani,et al.  Magnetic resonance imaging markers of Parkinson's disease nigrostriatal signature. , 2010, Brain : a journal of neurology.

[26]  H. Arai,et al.  18F-fluorodopa PET study of striatal dopamine uptake in the diagnosis of dementia with Lewy bodies , 2000, Neurology.

[27]  H. Berendse,et al.  Idiopathic hyposmia as a preclinical sign of Parkinson's disease , 2004, Annals of neurology.

[28]  N. Cairns,et al.  In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia , 2010, Neurology.

[29]  Johannes T Heverhagen,et al.  Diffusion tensor imaging in idiopathic REM sleep behavior disorder reveals microstructural changes in the brainstem, substantia nigra, olfactory region, and other brain regions. , 2010, Sleep.

[30]  Paola Piccini,et al.  The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins , 1999, Annals of neurology.

[31]  Francesco Fera,et al.  Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy. , 2006, Brain : a journal of neurology.

[32]  S. Gilman,et al.  PET measurement of cardiac and nigrostriatal denervation in Parkinsonian syndromes. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  B. Miller,et al.  11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration , 2007, Neurology.

[34]  I. Podreka,et al.  Measurement of the dopaminergic degeneration in Parkinson’s disease with [123I]β-CIT and SPECT , 1997 .

[35]  C Büchel,et al.  Motor reorganization in asymptomatic carriers of a single mutant Parkin allele: a human model for presymptomatic parkinsonism. , 2005, Brain : a journal of neurology.

[36]  J. Langston,et al.  Positron emission tomographic evidence for progression of human MPTP‐induced dopaminergic lesions , 1994, Annals of neurology.

[37]  C. Rowe,et al.  In Vitro Characterization of Pittsburgh Compound-B Binding to Lewy Bodies , 2007, The Journal of Neuroscience.

[38]  Daoqiang Zhang,et al.  Multimodal classification of Alzheimer's disease and mild cognitive impairment , 2011, NeuroImage.

[39]  R. Chervin,et al.  Decreased striatal dopaminergic innervation in REM sleep behavior disorder , 2000, Neurology.

[40]  Massimo Filippi,et al.  A diffusion tensor MRI study of patients with MCI and AD with a 2-year clinical follow-up , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[41]  Pablo Mir,et al.  Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: A clinical and electrophysiological study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[42]  C. DeCarli,et al.  What does fluorodeoxyglucose PET imaging add to a clinical diagnosis of dementia? , 2007, Neurology.

[43]  M. Viitanen,et al.  PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment , 2007, Neurology.

[44]  T. Krause,et al.  Impaired cardiac uptake of meta‐[123 I]iodobenzylguanidine in Parkinson's disease with autonomic failure , 1998, Acta neurologica Scandinavica.

[45]  Michael Schocke,et al.  White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion‐tensor imaging and voxel‐based morphometry study , 2011, Annals of neurology.

[46]  F. Tison,et al.  Oral zolmitriptan is effective in the acute treatment of cluster headache , 2000, Neurology.

[47]  J. Molinuevo,et al.  Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder , 2009, Movement disorders : official journal of the Movement Disorder Society.

[48]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[49]  C Kremser,et al.  Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy , 2003, Neurology.

[50]  F Barkhof,et al.  Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD , 2003, Neurology.

[51]  Thomas Hummel,et al.  Detection of presymptomatic Parkinson's disease: Combining smell tests, transcranial sonography, and SPECT , 2004, Movement disorders : official journal of the Movement Disorder Society.

[52]  S. Asenbaum,et al.  Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. , 1997, Journal of neural transmission. Supplementum.

[53]  Cindee M. Madison,et al.  Comparing predictors of conversion and decline in mild cognitive impairment , 2010, Neurology.

[54]  B. R. Bloem,et al.  Heterozygous carriers of a Parkin or PINK1 mutation share a common functional endophenotype , 2009, Neurology.

[55]  Pablo Mir,et al.  Patients with adult‐onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs) , 2007, Movement disorders : official journal of the Movement Disorder Society.

[56]  Vesna Sossi,et al.  PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. , 2005, Brain : a journal of neurology.

[57]  David Neil Manners,et al.  Apparent diffusion coefficient of the superior cerebellar peduncle differentiates progressive supranuclear palsy from Parkinson's disease.. Dec 15;23(16):2370-6.PMID: 18816803 , 2008 .

[58]  M. Albert,et al.  Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD , 2005, Neurology.

[59]  C. Jack,et al.  3D maps from multiple MRI illustrate changing atrophy patterns as subjects progress from mild cognitive impairment to Alzheimer's disease. , 2007, Brain : a journal of neurology.

[60]  Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation , 2005, Neurology.

[61]  J. Os,et al.  Cost of disorders of the brain in Europe 2010 , 2011, European Neuropsychopharmacology.

[62]  Daniela Berg,et al.  Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury. , 2002, Archives of neurology.

[63]  V. Sossi,et al.  Progression of dopaminergic dysfunction in a LRRK2 kindred , 2008, Neurology.

[64]  V. Sossi,et al.  Dopamine turnover increases in asymptomatic LRRK2 mutations carriers , 2010, Movement disorders : official journal of the Movement Disorder Society.

[65]  Efstathios D. Gennatas,et al.  Divergent network connectivity changes in behavioural variant frontotemporal dementia and Alzheimer's disease. , 2010, Brain : a journal of neurology.

[66]  K. Arai,et al.  Study of the rostral midbrain atrophy in progressive supranuclear palsy , 2003, Journal of the Neurological Sciences.

[67]  M. Greicius,et al.  Default-mode network activity distinguishes Alzheimer's disease from healthy aging: Evidence from functional MRI , 2004, Proc. Natl. Acad. Sci. USA.

[68]  Li Shen,et al.  Baseline MRI Predictors of Conversion from MCI to Probable AD in the ADNI Cohort , 2009, Current Alzheimer research.

[69]  M. Vendette,et al.  Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder , 2009, Neurology.

[70]  D. Goldstein,et al.  Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy. , 2008, Parkinsonism & related disorders.

[71]  J. Mazziotta,et al.  Cerebral metabolic and cognitive decline in persons at genetic risk for Alzheimer's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[72]  Nick C Fox,et al.  Conversion of amyloid positive and negative MCI to AD over 3 years , 2009, Neurology.

[73]  A. Convit,et al.  Hippocampal formation glucose metabolism and volume losses in MCI and AD , 2001, Neurobiology of Aging.

[74]  Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. , 2002, JAMA.

[75]  C Büchel,et al.  Morphometric fingerprint of asymptomatic Parkin and PINK1 mutation carriers in the basal ganglia , 2007, Neurology.

[76]  Nick C Fox,et al.  Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease , 2008, American Journal of Neuroradiology.

[77]  A J Lees,et al.  Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs) , 2009, Journal of Neurology, Neurosurgery, and Psychiatry.

[78]  J. Patterson,et al.  Successful antiparkinsonian medication withdrawal in patients with Parkinsonism and normal FP‐CIT SPECT , 2006, Movement disorders : official journal of the Movement Disorder Society.

[79]  J. Patterson,et al.  Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging , 2006, Nuclear medicine communications.

[80]  Satoshi Minoshima,et al.  Alzheimer's disease versus dementia with Lewy bodies: Cerebral metabolic distinction with autopsy confirmation , 2001, Annals of neurology.

[81]  Claude Nahmias,et al.  Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL‐PET study , 2003, Annals of neurology.

[82]  C. Becker,et al.  Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics , 2009, Neurobiology of Disease.

[83]  Paola Piccini,et al.  Clinical and subclinical dopaminergic dysfunction in PARK6‐linked parkinsonism: An 18F‐dopa PET study , 2002, Annals of neurology.

[84]  Vinod Menon,et al.  Functional connectivity in the resting brain: A network analysis of the default mode hypothesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.